financetom
Business
financetom
/
Business
/
UL Solutions Q2 Adjusted Earnings, Revenue Increase
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UL Solutions Q2 Adjusted Earnings, Revenue Increase
Jul 31, 2024 5:57 AM

08:42 AM EDT, 07/31/2024 (MT Newswires) -- UL Solutions ( ULS ) reported Q2 adjusted earnings Wednesday of $0.44 per diluted share, up from $0.42 a year earlier.

Analysts surveyed by Capital IQ expected $0.38.

Revenue for the quarter ended June 30 was $730 million, compared with $689 million a year earlier.

Analysts surveyed by Capital IQ expected $719.7 million.

Price: 48.00, Change: +2.11, Percent Change: +4.60

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
California Water Service Group Reaffirms $215 Million Investment Commitment to PFAS Treatment
California Water Service Group Reaffirms $215 Million Investment Commitment to PFAS Treatment
Apr 19, 2024
04:00 AM EDT, 04/19/2024 (MT Newswires) -- California Water Service Group ( CWT ) reiterated late Thursday its commitment to invest $215 million in the treatment of per- and polyfluorinated substances, or PFAS. The decision comes after the California Public Utilities Commission dismissed the group's request to modify a previously approved PFAS-expense memorandum account, to include capital-related costs for the...
NeoGames Heads Toward Closing Aristocrat Leisure Acquisition Next Week
NeoGames Heads Toward Closing Aristocrat Leisure Acquisition Next Week
Apr 19, 2024
04:25 AM EDT, 04/19/2024 (MT Newswires) -- NeoGames ( NGMS ) confirmed late Thursday that all necessary regulatory approvals required to complete its merger with Aristocrat Leisure have been received or waived. The company also said it has received all antitrust and foreign investment regulatory clearances. The move marks a further step toward completion of the acquisition before the final...
Takeda Pharmaceutical Receives FDA Approval for Single-Dose Injection Crohn's Disease Treatment
Takeda Pharmaceutical Receives FDA Approval for Single-Dose Injection Crohn's Disease Treatment
Apr 19, 2024
04:13 AM EDT, 04/19/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Thursday it received US Food and Drug Administration approval for subcutaneous injection of Entyvio as a maintenance therapy in adults with moderately to severely active Crohn's disease following induction therapy with intravenous Entyvio. The approval followed a 409-patient phase 3 trial of Entyvio in which 48% of...
Tungray Technologies Prices IPO at $4 a Share
Tungray Technologies Prices IPO at $4 a Share
Apr 19, 2024
04:04 AM EDT, 04/19/2024 (MT Newswires) -- Tungray Technologies said late Thursday it priced its initial public offering of approximately 1.3 million class A ordinary shares at $4 per share for expected gross proceeds of about $5 million. The underwriters have been granted a 45-day option to purchase up to 187,500 additional shares. Closing of the offering is expected to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved